作者: Amruta Bedekar , Karan Shah , Mattheos Koffas
DOI: 10.1016/S0065-2164(10)71002-9
关键词:
摘要: Natural products such as plant extracts and complex microbial secondary metabolites have recently attracted the attention of scientific world for their potential use drugs treating chronic diseases Type II diabetes. Non-Insulin-Dependent Diabetes Mellitus (NIDDM) or diabetes has complicated basis various treatment options, each targeting different mechanism action. One option relies on digestive enzyme inhibition. Almost all currently used clinically inhibitors are bacterial metabolites. However in most cases understanding complete biosynthetic pathways remains a challenge. The significant side effects that restricted usage. Hence, many active being investigated more effective with fewer effects. Flavonoids, terpenoids, glycosides few to name class. Many these proven enzymes but large scale production technical conundrum. Their successful heterologous simple host bacteria scalable quantities gives new dimension continuously research better type Looking at existing methods mass level latest efforts effectively discover is subject this book chapter.